Antibiotic resistance is an ever-increasing global threat to public health by jeopardizing the treatment of infectious dis-eases.An emergency demand for new mechanism antimicrobial agents have been launching to effectively treat the infections caused by resistant strains.Iclaprim a new Gram-positive bacteria drug developed by Arpida,a novel 2,4-diaminopyrimidine with potent rapidly bactericidal activity against Gram-positive pathogens.Its clinical trials have been approved for the treatment of skin and soft tissue infec-tions and hospital-acquired pneumonia in Gram-positive bacteria and phase III trials have been completed.Studies have shown that Icl-aprim has good tissue distribution,good antibacterial activity in vivo and in vitro,and Gram-positive bacteria activity is non-inferior to vancomycin.The incidence of adverse reactions is similar to that of vancomycin,no nephrotoxicity.The antimicrobial spectrum includes all Gram-positive bacteria,some Gram-negative,atypical pathogens and pneumocystis carinii.Because of its wide distribution in the body,high protein binding rate,high pulmonary concentration,less adverse drug reactions and good tolerance,Iclaprim is expected to become a therapeutic drug for the treatment of Gram-positive bacteria resistant bacterial infections.In this study,the pharmacological,antimicrobial,antimicrobial,and pharmacokinetics aspects of etopol were reviewed,to provide reference for the development and treat-ment of new therapeutic drugs for Gram-positive bacteria resistant bacterial infections.
NETL
NSTL
万方数据
